On May 6, 2025 Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, reported that it will present new and strengthened circVec circular RNA in vivo data at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) annual meeting 2025 taking place in New Orleans, USA, 13-17 May 2025 (Press release, Circio, MAY 6, 2025, View Source [SID1234652505]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the poster presentation, Circio will showcase the latest in vivo results for the circVec synthetic DNA and AAV gene therapy platform. circVec circular RNA-based vectors have the potential to substantially boost protein expression level and durability for both viral and non-viral gene and cell therapy. Recently generated in vivo data further validates and strengthens the circVec system in specific settings, and provides important context to prioritize development areas and partnering strategy.
Title of presentation:
CircVec: a powerful circular RNA expression platform to enhance viral and non-viral gene and cell therapies
Time and poster number:
13 May 2025, 18:00-19:30hrs CDT, poster #655
Location:
Ernest N. Morial Convention Center, New Orleans, Louisiana, USA
The poster will be made available on Circio´s webpage after the presentation